Breaking News Instant updates and real-time market news.

REGN

Regeneron

$508.71

0.3 (0.06%)

, SNY

Sanofi

$47.56

-0.53 (-1.10%)

09:01
07/31/17
07/31
09:01
07/31/17
09:01

Regeneron indicated lower after Sanofi earnings report, says Piper Jaffray

Piper Jaffray analyst Edward Tenthoff says shares of Regeneron (REGN) are indicated lower after partner Sanofi (SNY) reported Q2 U.S. Dupixent sales of $30M in adults with atopic dermatitis. This was essentially in line with the consensus estimate of $33M, Tenthoff tells investors in a research note. He adds that over 5,100 physicians have prescribed and over 13,000 atopic dermatitis patients have been prescribed Dupixent as of July 26. The analyst views the launch stats as impressive and reiterates an Overweight rating on Regeneron with a $557 price target.

REGN

Regeneron

$508.71

0.3 (0.06%)

SNY

Sanofi

$47.56

-0.53 (-1.10%)

  • 31

    Jul

  • 03

    Aug

REGN Regeneron
$508.71

0.3 (0.06%)

06/27/17
LEER
06/27/17
NO CHANGE
Target $573
LEER
Outperform
Regeneron price target raised to $573 from $493 at Leerink
Leerink analyst Geoffrey Porges raised his price target for Regeneron Pharmaceuticals to $573 to reflect higher expected sales of Dupixent, lower expected sales of Eylea due to some erosion by RTH258 starting in 2019, and including for the first time revenue from REGN2810. Regeneron shares are likely to benefit from "positive" Q2 results and further pipeline disclosures throughout the year, Porges tells investors in a research note. He reiterates an Outperform rating on the name.
06/30/17
BTIG
06/30/17
NO CHANGE
BTIG
Regeneron price target raised to $540 from $480 at BTIG
BTIG analyst Dane Leone increased his price target on Regeneron as he believes that data on the company's nesvacumab drug, and a study of its Dupixent drug in asthma will be positive. The analyst expects investors to become more upbeat about the potential of its oncology treatments. He keeps a Buy rating on the stock.
07/19/17
BOFA
07/19/17
NO CHANGE
Target $593
BOFA
Buy
Regeneron added to US 1 List at BofA/Merrill
BofA/Merrill analyst Ying Huang added Regeneron to the US 1 List saying he expects upside to be driven by a strong base of business, higher Dupixent sales, and a best-in-class pipeline that will drive long-term growth. Huang rates Regeneron a Buy with a $593 price target.
07/28/17
ADAM
07/28/17
NO CHANGE
Target $522
ADAM
Buy
Regeneron price target raised to $522 from $484 at Canaccord
Canaccord analyst John Newman raised his price target on Regeneron to $522 from $484 ahead of Q2 results as he expects the "impressive" launch of Dupixent to help it beat consensus estimates. He also believes investors sentiment seems to suggest the stable Eylea revenues will be viewed as positive. Newman reiterated his Buy rating on Regeneron shares.
SNY Sanofi
$47.56

-0.53 (-1.10%)

06/27/17
06/27/17
NO CHANGE

Large cap pharma could benefit from upcoming executive order, says Wells Fargo
Wells Fargo says that, based on press reports, large cap pharma could benefit from President Trump's upcoming executive order on drug pricing. The firm says the articles indicate that the order will not create major reforms or do anything to lower consumers' costs or solve current pricing issues. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
06/27/17
FBCO
06/27/17
NO CHANGE
FBCO
Outperform
Alnylam price target raised to $96 from $90 at Credit Suisse
Credit Suisse analyst Alethia Young increased her probability of success for Alnylam's (ALNY) givosian in porphyria to 60% from 40% and keeps an estimate of unadjusted peak sales of $475M, while also noting that the fact that Sanofi (SNY) did not opt into the porphyria program, meaning Alnylam receives full economics. Given the higher chances ascribed to success, Young raised her price target on Alnylam to $96 from $90 and keeps an Outperform rating on the stock.
07/10/17
PIPR
07/10/17
NO CHANGE
Target $126
PIPR
Overweight
Alnylam shares overreacting to ALT elevations in OLE data, says Piper Jaffray
Alnylam (ALNY) and partner Sanofi (SNY) presented new Phase II open-label extension study data on 33 hemophilia patients being treated with fitusiran and reported that eleven patients reported asymptomatic ALT increases, up from three observed in its ASH meeting update, noted Piper Jaffray analyst Edward Tenthoff. However, he thinks the stock is overreacting, as the liver enzyme elevations were asymptomatic and largely reversed within one month, he tells investors. Tenthoff, who also sees the efficacy data as encouraging, reiterates his Overweight rating and $126 price target on Alnylam shares.
07/14/17
WELS
07/14/17
NO CHANGE
Target $41
WELS
Outperform
Wells says smallpox vaccine deal an 'excellent fit' for Emergent BioSolutions
Wells Fargo analyst David Maris said Emergent BioSolutions' (EBS) deal to acquire the ACAM2000 smallpox vaccine business of Sanofi (SNY) is "an excellent fit" and he is "encouraged" by its ability to identify and make a deal for such a "solid target." Maris keeps an Outperform rating and $41 price target on Emergent BioSolutions.

TODAY'S FREE FLY STORIES

T

AT&T

$34.64

0.13 (0.38%)

, TWX

Time Warner

$87.71

-1.01 (-1.14%)

17:45
11/20/17
11/20
17:45
11/20/17
17:45
Hot Stocks
AT&T CEO says giving up control of CNN is a 'non-starter' »

Says plenty of solutions…

T

AT&T

$34.64

0.13 (0.38%)

TWX

Time Warner

$87.71

-1.01 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

BBY

Best Buy

$56.35

0.52 (0.93%)

17:45
11/20/17
11/20
17:45
11/20/17
17:45
Conference/Events
Best Buy management to meet with SunTrust »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

T

AT&T

$34.64

0.13 (0.38%)

, TWX

Time Warner

$87.71

-1.01 (-1.14%)

17:43
11/20/17
11/20
17:43
11/20/17
17:43
Hot Stocks
AT&T CEO says DOJ suit 'defies logic' »

Says has offered…

T

AT&T

$34.64

0.13 (0.38%)

TWX

Time Warner

$87.71

-1.01 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

RELY

Real Industry

$0.52

0.1643 (45.92%)

17:38
11/20/17
11/20
17:38
11/20/17
17:38
Hot Stocks
Real Industry, Real Alloy receive court approval of 'first day' motions »

Real Industry announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RAVN

Raven

$34.65

0.85 (2.51%)

17:34
11/20/17
11/20
17:34
11/20/17
17:34
Earnings
Raven reports Q3 EPS 33c, consensus 23c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

ONTX

Onconova

$1.70

0.01 (0.59%)

17:34
11/20/17
11/20
17:34
11/20/17
17:34
Syndicate
Breaking Syndicate news story on Onconova »

Onconova files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

ONTX

Onconova

$1.70

0.01 (0.59%)

17:33
11/20/17
11/20
17:33
11/20/17
17:33
Syndicate
Breaking Syndicate news story on Onconova »

Onconova files $84.55M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

MLNX

Mellanox

$51.05

1 (2.00%)

17:31
11/20/17
11/20
17:31
11/20/17
17:31
Hot Stocks
Starboard Value reports 9.8% stake in Mellanox »

Starboard has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 05

    Dec

  • 06

    Dec

ASYS

Amtech Systems

$14.12

0.93 (7.05%)

, PANW

Palo Alto Networks

$142.53

-0.19 (-0.13%)

17:27
11/20/17
11/20
17:27
11/20/17
17:27
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: Amtech…

ASYS

Amtech Systems

$14.12

0.93 (7.05%)

PANW

Palo Alto Networks

$142.53

-0.19 (-0.13%)

URBN

Urban Outfitters

$28.27

0.37 (1.33%)

CLSN

Celsion

$2.14

0.14 (7.00%)

SNSS

Sunesis

$2.87

0.01 (0.35%)

HAIN

Hain Celestial

$40.89

1.05 (2.64%)

NSRGY

Nestle

$85.14

0.03 (0.04%)

A

Agilent

$69.96

1.17 (1.70%)

BECN

Beacon Roofing

$56.28

0.65 (1.17%)

INTU

Intuit

$157.78

1.23 (0.79%)

SNCR

Synchronoss

$11.14

0.76 (7.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 30

    Nov

  • 11

    Dec

  • 11

    Dec

  • 17

    Jan

  • 17

    Jan

SNGX

Soligenix

$2.24

0.02 (0.90%)

17:23
11/20/17
11/20
17:23
11/20/17
17:23
Syndicate
Breaking Syndicate news story on Soligenix »

Soligenix files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTIB

CTI Industries

$3.56

-0.269 (-7.03%)

17:23
11/20/17
11/20
17:23
11/20/17
17:23
Hot Stocks
CTI Industries names Frank Cesario CFO »

CTI Industries announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEDG

SolarEdge

$38.90

1.35 (3.60%)

17:22
11/20/17
11/20
17:22
11/20/17
17:22
Hot Stocks
SolarEdge chairman, CEO Sella diagnosed with colon cancer »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 28

    Nov

  • 29

    Nov

STLY

Stanley Furniture

$0.93

0.0349 (3.92%)

17:20
11/20/17
11/20
17:20
11/20/17
17:20
Hot Stocks
Breaking Hot Stocks news story on Stanley Furniture »

Stanley Furniture trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLAD

Gladstone Capital

$9.76

-0.02 (-0.20%)

17:09
11/20/17
11/20
17:09
11/20/17
17:09
Earnings
Gladstone Capital reports Q4 NII 21c, consensus 21c »

Reports NAV per share…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

T

AT&T

$34.64

0.13 (0.38%)

, TWX

Time Warner

$87.71

-1.01 (-1.14%)

17:07
11/20/17
11/20
17:07
11/20/17
17:07
Hot Stocks
Breaking Hot Stocks news story on AT&T, Time Warner »

Department of Justice…

T

AT&T

$34.64

0.13 (0.38%)

TWX

Time Warner

$87.71

-1.01 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

LMT

Lockheed Martin

$314.65

4.95 (1.60%)

17:07
11/20/17
11/20
17:07
11/20/17
17:07
Hot Stocks
Lockheed Martin awarded $122.3M U.S. Navy contract »

ockheed Martin Rotary and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

ZTO

ZTO Express

$17.00

0.17 (1.01%)

17:02
11/20/17
11/20
17:02
11/20/17
17:02
Earnings
Breaking Earnings news story on ZTO Express »

ZTO Express sees Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

MSG

Madison Square Garden

$215.00

-3.46 (-1.58%)

17:01
11/20/17
11/20
17:01
11/20/17
17:01
Hot Stocks
Madison Square Garden acquires Obscura Digital, terms not disclosed »

The Madison Square Garden…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZTO

ZTO Express

$17.00

0.17 (1.01%)

17:01
11/20/17
11/20
17:01
11/20/17
17:01
Earnings
ZTO Express reports Q3 EPS 15c, consensus 15c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

VICL

Vical

$1.98

0.04 (2.06%)

16:59
11/20/17
11/20
16:59
11/20/17
16:59
Hot Stocks
Breaking Hot Stocks news story on Vical »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BECN

Beacon Roofing

$56.28

0.65 (1.17%)

16:57
11/20/17
11/20
16:57
11/20/17
16:57
Earnings
Beacon Roofing sees FY18 adjusted EPS $2.95-$3.25, consensus $2.57 »

Sees FY18 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

ABC

AmerisourceBergen

$77.46

-1.38 (-1.75%)

16:56
11/20/17
11/20
16:56
11/20/17
16:56
Earnings
AmerisourceBergen sees FY18 revenue up 8%-11% following H.D. Smith acquisition »

Consensus $164.76B. Based…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 29

    Nov

ABC

AmerisourceBergen

$77.46

-1.38 (-1.75%)

16:53
11/20/17
11/20
16:53
11/20/17
16:53
Hot Stocks
AmerisourceBergen to acquire H.D. Smith for $815M in cash »

AmerisourceBergen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 29

    Nov

RGEN

Repligen

$33.26

-0.14 (-0.42%)

16:53
11/20/17
11/20
16:53
11/20/17
16:53
Conference/Events
Repligen management to meet with Stephens »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

BKI

Black Knight

$45.80

0.3 (0.66%)

16:51
11/20/17
11/20
16:51
11/20/17
16:51
Syndicate
Black Knight files to sell 5M shares of common stock for holders »

Goldman Sachs & Co. …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.